Company news

CelLBxHealth plc news in 2022

CelLBxHealth plc's news releases, calls and decks from 2022, newest first.

View company

Two Parsortix posters presented at SABCS

December 12, 2022

Issue of Equity

December 2, 2022

Multiple downstream analysis techniques for CTCs

November 2, 2022

Parsortix poster presented at ISLB meeting

October 24, 2022

Streamlining of operations to increase cash runway

October 18, 2022

TR-1: Notification of major holdings

October 17, 2022

First regional distribution agreement

October 12, 2022

Positive headline results from ovarian study

September 29, 2022

Study using Parsortix in head and neck cancer

September 28, 2022

New poster presented at ASCP Meeting

September 13, 2022

Novel assay predicts malignancy in pelvic mass

September 12, 2022

Novel insight into metastasis in NSCLC patients

July 28, 2022

New study of Parsortix system in NSCLC

July 20, 2022

Director/PDMR Shareholding

July 19, 2022

Results of Capital Raise

July 15, 2022

Retail Offer via PrimaryBid

July 14, 2022

Result of 2022 Annual General Meeting

June 29, 2022

Spread of breast cancer accelerates during sleep

June 27, 2022

Secured contract from pharma services customer

June 22, 2022

Predicting immunotherapy response in SCLC

June 16, 2022

Potential role of invasive cellular protrusions

June 14, 2022

Partnership with major United States urology group

May 30, 2022

Molecular characterisation of CTCs

May 27, 2022

ANGLE receives FDA clearance for Parsortix

May 25, 2022

Prostate Cancer UK funds new study using Parsortix

May 20, 2022

Poster on Parsortix system presented at AACR 2022

April 14, 2022

Identifying drug targets in cancer metastasis

April 1, 2022

Rapid information on patient response to therapies

March 29, 2022

Identifying therapeutic targets in TNBC patients

March 25, 2022

Update on laboratory accreditation

March 15, 2022

Potential in immunotherapy treatment selection

January 21, 2022

Concordance of Parsortix with tissue biopsy

January 17, 2022

Update on lab accreditation and ovarian study

January 13, 2022

Insight into drug resistance in NSCLC

January 10, 2022

Calls in 2022

Decks in 2022